8-K: TScan Therapeutics Reports Positive Clinical Trial Data and Financial Results for 2023

TScan Therapeutics announced positive results from its Phase 1 clinical trials for hematologic malignancies, progress in its solid tumor program, and its financial results for the fourth quarter and full year 2023.

Summary

• TScan Therapeutics reported its financial results for the fourth quarter and full year ended December 31, 2023, alongside a business update.
• The company presented updated data from its Phase 1 study of TSC-100 and TSC-101 for hematologic malignancies, showing 100% of patients in the treatment arms are relapse-free with complete donor chimerism.
• Two additional Investigational New Drug (IND) applications were cleared for the Solid Tumor Program, specifically TSC-201-B0702 and TSC-204-A0101.
• The solid tumor clinical trial is actively enrolling patients, with initial data expected in 2024.
• TScan's leadership team has expanded with key appointments and promotions.
• The company's cash, cash equivalents, and marketable securities are expected to fund operations into 2026.
• Revenue for the fourth quarter of 2023 was $7.2 million, compared to $3.1 million in the same period of 2022, and full-year revenue was $21.0 million, compared to $13.5 million in 2022.
• Research and development expenses for the fourth quarter of 2023 were $22.4 million, compared to $15.6 million in 2022, and full-year expenses were $88.2 million, compared to $59.8 million in 2022.
• The net loss for the fourth quarter of 2023 was $19.6 million, compared to $18.7 million in 2022, and the full-year net loss was $89.2 million, compared to $66.2 million in 2022.
• As of December 31, 2023, TScan had $192.0 million in cash, cash equivalents, and marketable securities.

Sentiment

Score: 8

Explanation: The document presents very positive clinical trial results, significant progress in the solid tumor program, and a strong cash position. The increase in revenue is also a positive sign. However, the increase in R&D expenses and net loss are typical for a clinical-stage biotech company, which tempers the overall sentiment slightly.

Positives

• The Phase 1 heme malignancies study shows 100% of treatment-arm patients are relapse-free.
• The company has received FDA clearance for two additional INDs for its Solid Tumor Program.
• TScan is on track to dose the first patient in its Phase 1 solid tumor program in the first quarter of 2024.
• The company's cash position is strong, expected to fund operations into 2026.
• Revenue has increased significantly year-over-year, driven by collaboration agreements.
• The company is expanding its ImmunoBank, which increases patient eligibility for multiplexed therapy.

Negatives

• Research and development expenses have increased significantly year-over-year.
• The company reported a net loss of $89.2 million for the full year 2023.
• Two patients in the control arm of the heme malignancies study relapsed, and one died due to relapse.

Risks

• Clinical trial results may not be predictive of future outcomes.
• The company's ability to enroll patients in clinical trials within expected timelines is a risk.
• There are risks associated with developing and commercializing TCR-T therapy candidates.
• The company faces competition in the biopharmaceutical industry.
• The company's ability to obtain and maintain intellectual property protection is a risk.
• The company's future capital requirements and need for additional financing are risks.

Future Outlook

TScan expects to continue advancing its clinical programs, including opening expansion cohorts for the heme malignancies program, dosing the first patient in the solid tumor program, and expanding its ImmunoBank. The company anticipates sharing clinical data throughout 2024 and 2025.

Management Comments

• Gavin MacBeath, Ph.D., Chief Executive Officer, stated that the advancements made in 2023 have set the stage for a momentous year ahead.
• Gavin MacBeath, Ph.D., also noted the encouraging results from the Phase 1 heme malignancies study, with no relapses in the treatment arms.
• Debora Barton, M.D., Chief Medical Officer, mentioned that the company is on-track to treat the first patient in the Phase 1 solid tumor program this month.
• Debora Barton, M.D., also emphasized the importance of a multi-targeted approach to eradicate solid tumors.

Industry Context

TScan's focus on TCR-T therapies aligns with the growing interest in personalized cancer treatments. The company's approach to multiplexed therapy addresses the challenge of tumor heterogeneity, a significant hurdle in solid tumor treatment. The positive results in hematologic malignancies and the expansion into solid tumors position TScan as a notable player in the cell therapy space.

Comparison to Industry Standards

• The 100% relapse-free rate in the treatment arm of TScan's Phase 1 heme malignancies study is a very positive result compared to standard treatments like allogeneic hematopoietic cell transplantation alone, where relapse rates can be significant.
• Companies like Kite Pharma and Juno Therapeutics have pioneered CAR-T cell therapies, but TScan's TCR-T approach targets a broader range of antigens, potentially addressing a larger patient population.
• The development of multiplexed TCR-T therapies is a novel approach, differentiating TScan from companies focusing on single-target therapies.
• The expansion of the ImmunoBank is similar to efforts by other companies to create libraries of therapeutic targets, but TScan's focus on TCRs provides a unique angle.
• The financial results show a significant increase in revenue due to collaboration agreements, which is a positive sign for the company's business model, but the increase in R&D expenses is typical for a clinical-stage biotech company.

Management Changes

Stakeholder Impact

• Shareholders will likely view the positive clinical trial results and strong cash position favorably.
• Employees may be encouraged by the company's progress and expansion.
• Patients with cancer may benefit from the development of new treatment options.
• The company's collaboration partners may see the progress as a positive development.

Next Steps

• Open expansion cohorts at the recommended Phase 2 dose level for the heme malignancies program in the third quarter of 2024.
• Complete Phase 1 enrollment and report one-year clinical and translational data for the heme malignancies program in 2024.
• Initiate registration trial and report two-year relapse data for the heme malignancies program in 2025.
• Dose the first patient in the Phase 1 solid tumor program in the first quarter of 2024.
• Share initial data on patients from both singleplex and multiplex cohorts in the solid tumor program in 2024.
• Continue to expand the ImmunoBank with additional IND filings throughout 2024.
• Report long-term duration of response data for multiplexed therapy in the solid tumor program in 2025.

Key Dates

Keywords

TCR-T, T cell therapy, cancer, hematologic malignancies, solid tumors, clinical trial, IND, ImmunoBank, relapse, chimerism, biopharmaceutical